Glaxo Reports 45% Survival Rate in Melanoma Drug Trial
September 29 2014 - 6:42AM
Dow Jones News
LONDON-- GlaxoSmithKline PLC (GSK.LN) Monday said a phase III
study of its melanoma treatment Tafinlar showed 45% of patients
treated with the drug were still alive after two years.
Shares at 1109 GMT, down 14 pence, or 1%, at 1,418 pence valuing
the company at GBP68.8 billion ($111.8 billion).
-Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter:
@RoryGallivan
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2024 to May 2024
GSK (NYSE:GSK)
Historical Stock Chart
From May 2023 to May 2024